Biogen (BIIB) Net Margin (2009 - 2026)

Biogen (BIIB) has reported Net Margin for 18 consecutive years, with 12.89% the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Margin rose 300.0% year-over-year to 12.89%; the TTM figure through Mar 2026 stood at 13.81% (down 126.0% YoY), while the FY2025 annual figure was 13.07%, down 380.0% from the prior year.
• Net Margin came in at 12.89% for Q1 2026 at Biogen, up from 2.15% in the prior quarter.
• The five-year high for Net Margin was 45.59% in Q3 2022, with the low at 2.54% in Q3 2023.
• Average Net Margin over 5 years is 17.48%, with a median of 16.13% recorded in 2023.
• Across the five-year window, Net Margin surged 5044 bps in 2022 and tumbled 4813 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 21.97% in 2022, then sank by 53 bps to 10.43% in 2023, then increased by 4 bps to 10.86% in 2024, then slumped by 120 bps to 2.15% in 2025, then surged by 701 bps to 12.89% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 12.89%, 2.15%, and 18.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.